SENL103

· Hebei Senlang Biotechnology Inc., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SENL103, covering 2026-02-19 to 2026-02-19. Get the full timeline:

Most recent: Clinical Trial Update: Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. [Phase 1, Phase 2]

See pricing